FibroMeter™ : blood markers to assess degree of fibrosis

 Interview of Pr Paul Calès, Hepatogastroenterology Department, Angers Hospital, FRANCE.





Could you briefly tell us about the main objectives of your study?

Why did you choose to focus on these objectives?


In 1997, we developed the first hepatic fibrosis tests, but at the time they related to particular causes.

In this case, it was to develop cause-specific tests, and to improve the diagnostic targets.


Could you present the inclusion criteria and also the targeted population?

Why did you chose these criteria?


There were two types of population:

  • Viral Hepatitis C and B on one hand,

  • And alcoholic hépatopathies on the other hand.

Each patient needed a liver biopsy, which was the reference.  There were 51 blood markers. A clinical criterion was that they must have decompensated cirrhosis or any anti-fibrosis treatment.


Could you briefly outline the results?


There were two types of result, since there were two diagnostic targets.


There was significant fibrosis, and the fibrosis area. With regard to the first population of viral hepatitis patients, there was a test population of 383 patients and a control population of 120 patients.

The AUROC for significant fibrosis was 0.88, which is very good, and the R2 coefficient for the fibrosis area was a satisfactory 0.64.


With regard to the population with alcoholic hepatopathy, there were only 95 patients, because these are less common patients from the point of view of biopsies, but the AUROC for significant fibrosis was an excellent 0.96, and the correlation coefficient for the fibrosis area was also excellent: 0.92.


Which key points of the study are to be remembered?

In conclusion, what improvements will your study bring to clinical practice and patients?


For the advanced points of the study, there were two main messages.

  • Firstly, there was the test for significant fibrosis, whose performance was confirmed, in about fifteen studies, most of which were independent.

  • Concerning the fibrosis area test, this was also a significant advance, but it requires confirmation.

Concerning the practical clinical consequences, there are many results because, with these results confirmed, these tests became accepted practice according to HAS (French Health Authority) recommendations.

It is now possible to use a blood test as a first-line diagnostic solution in adults with Hepatitis C without comorbidity.




Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. Hepatology. 2005;42(6):1373-81.